119 related articles for article (PubMed ID: 23769430)
1. [Updates on pathology of soft tissue tumors].
Yu L; Wang J
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):145-6. PubMed ID: 23769430
[No Abstract] [Full Text] [Related]
2. Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
Mughal TI; Goldman JM
Clin Med (Lond); 2006; 6(6):526-8. PubMed ID: 17228548
[No Abstract] [Full Text] [Related]
3. Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis?
Erre GL; Pardini S; Cuccuru L; Taras L; Passiu G
Joint Bone Spine; 2015 Jan; 82(1):72-3. PubMed ID: 25059880
[No Abstract] [Full Text] [Related]
4. Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Murphy M; Close J; Lottenberg R; Rajasekhar A
Am J Med Sci; 2014 Mar; 347(3):254-5. PubMed ID: 24553361
[No Abstract] [Full Text] [Related]
5. [Tyrosine kinase inhibitors].
Yagasaki F
Nihon Naika Gakkai Zasshi; 2007 Jul; 96(7):1411-9. PubMed ID: 17682429
[No Abstract] [Full Text] [Related]
6. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
7. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.
Siegel A
Gastroenterology; 2008 Sep; 135(3):733-5. PubMed ID: 18692053
[No Abstract] [Full Text] [Related]
8. Management of gastrointestinal stromal tumor: the imatinib era and beyond.
Parikh PM; Gupta S
Indian J Cancer; 2013; 50(1):31-40. PubMed ID: 23713042
[TBL] [Abstract][Full Text] [Related]
9. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
[No Abstract] [Full Text] [Related]
10. [Effectiveness of imatinib mesylate in treatment for dermatofibroma protuberans].
Moiseenko VM; Chudenko VA; Orlova RV; Imianitov EN; Matsko DE; Gafton GI; Kochnev VA; Protsenko SA; Mikhaĭlichenko TD; Nogaeva TKh
Vopr Onkol; 2008; 54(5):656-60. PubMed ID: 19069485
[No Abstract] [Full Text] [Related]
11. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Imataki O
Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
[No Abstract] [Full Text] [Related]
12. Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
Druker BJ
J Hematother Stem Cell Res; 2001 Dec; 10(6):721-4. PubMed ID: 11798498
[No Abstract] [Full Text] [Related]
13. [Systemic therapy of soft tissue sarcomas].
Pink D; Bertz-Lepel J; Reichardt P
Pathologe; 2011 Feb; 32(1):65-71. PubMed ID: 21053001
[TBL] [Abstract][Full Text] [Related]
14. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
Utikal J; Ugurel S; Kurzen H; Erben P; Reiter A; Hochhaus A; Nebe T; Hildenbrand R; Haberkorn U; Goerdt S; Schadendorf D
Arch Dermatol; 2007 Jun; 143(6):736-40. PubMed ID: 17576939
[TBL] [Abstract][Full Text] [Related]
15. [Molecular targeted therapy for malignant brain tumors].
Okamura T; Kurisu K
Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
[No Abstract] [Full Text] [Related]
16. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.
Levitzki A
Annu Rev Pharmacol Toxicol; 2013; 53():161-85. PubMed ID: 23043437
[TBL] [Abstract][Full Text] [Related]
17. [Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor].
Calvo E; Fernández FJ; Forteza J; Brugarolas A
Med Clin (Barc); 2002 Sep; 119(10):396-7. PubMed ID: 12372175
[No Abstract] [Full Text] [Related]
18. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?
Josselin-Mahr L; Werbrouck-Chiraux A; Garderet L; Cabane J
Rheumatology (Oxford); 2014 Feb; 53(2):378-9. PubMed ID: 23893665
[No Abstract] [Full Text] [Related]
19. Pulmonary toxicities of tyrosine kinase inhibitors.
Peerzada MM; Spiro TP; Daw HA
Clin Adv Hematol Oncol; 2011 Nov; 9(11):824-36. PubMed ID: 22252615
[TBL] [Abstract][Full Text] [Related]
20. Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Gonçalves A; Monges G; Yang Y; Palmerini F; Dubreuil P; Noguchi T; Jacquemier J; Di Stefano D; Delpero JR; Sobol H; Bertucci F
J Natl Cancer Inst; 2006 Apr; 98(8):562-3. PubMed ID: 16622127
[No Abstract] [Full Text] [Related]
[Next] [New Search]